<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421096</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCOL 0401</org_study_id>
    <nct_id>NCT00421096</nct_id>
  </id_info>
  <brief_title>Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer</brief_title>
  <acronym>GEMCOL</acronym>
  <official_title>Stage IB2 to IVA Uterine Cervical Cancer: Phase 2 Study to Assess a New Therapeutic Sequence Associating a Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin +&#xD;
      radiotherapy followed by an adjuvant chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems of recruitment&#xD;
  </why_stopped>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years after the end of study treament</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>5 years after the end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>untill 5 years after study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Uterine Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>patient with cervix cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive gemcitabine + cisplatin + radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.</description>
    <arm_group_label>patient with cervix cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)&#xD;
+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area</description>
    <arm_group_label>patient with cervix cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration</description>
    <arm_group_label>patient with cervix cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years old&#xD;
&#xD;
          -  Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB&gt; or = 4 cm to IV,&#xD;
             according to FIGO classification) histologically proven&#xD;
&#xD;
          -  Measurable lesions,clinically and by MRI assessed&#xD;
&#xD;
          -  PS-WHO &lt; or = 2 ou Karnofsky Index &gt;70 per cent&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Hematologic function: leukocytes &lt; or = 3 G/l, polynuclear neutrophil leukocytes &gt; or&#xD;
             = 1.5 G/l, platelets &gt; or = 100 G/l, hemoglobin &gt; or = 10 g/dl&#xD;
&#xD;
          -  Hepatic function: ASAT and ALAT &lt; 2.5 ULN&#xD;
&#xD;
          -  Renal function: creatininemia &lt; 1.5 ULN, clearance &gt; 60 ml/min&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Contraception&#xD;
&#xD;
          -  Written informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IB &lt; 4 cm or IVB&#xD;
&#xD;
          -  Other histology than epidermoid or adenocarcinoma&#xD;
&#xD;
          -  Distant metastases, including sus-clavicular adenopathy&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Auto-immune disease&#xD;
&#xD;
          -  Peripheric neuropathy, autograft or homograft, psychiatric disease&#xD;
&#xD;
          -  Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma&#xD;
             in situ)&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Other clinical trial with an experimental drug&#xD;
&#xD;
          -  Known positive serology (HIV, HbC, HbS)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BELKACEMI Yazid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Leonard de Vinci</name>
      <address>
        <city>Dechy</city>
        <zip>59187</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

